U03, Piano: P04, Stanza: 4047
Piazza della Scienza, 2 - 20126 MILANO
Piazza della Scienza, 2 - 20126 MILANO
U03, Piano: P04, Stanza: 4048
Piazza della Scienza, 2 - 20126 MILANO
Piazza della Scienza, 2 - 20126 MILANO
PERI FRANCESCO
Ruolo:
Professore ordinario
Settore scientifico disciplinare:
CHIMICA ORGANICA (CHIM/06)
Afferenza:
E-mail:
Telefono:
0264483453
0264483455
0264483455
Stanza:
Biografia
Full Professor in of Organic and Medicinal Chemistry at the Department of Biotechnology and Biosciences, University of Milano-Bicocca.
Permanent professorship at the Ecole Normale Supérieure (ENS) of Lyon (France) where he teaches a course of Medicinal Chemistry (Master level). In 2012, professorship in Organic Chemistry at the University Paris 5, and in 2012 he was Visiting Professor at the Department of Chemistry, University of California, Davis (USA).
Bibliometrics: 105 publications in international journals, 3151 citations, H-index= 33, (21 since 2014), i10-index= 71.
2015-2018, coordination of the H2020-funded MSCA-ETN project TOLLerant (“Toll-Like Receptor 4 activation and function in diseases: an integrated chemical-biology approach”, GA number 642157).
The research activity of the lab focused in last year in the design, synthesis and biological characterization of small molecules (mainly cationic and anionic glycolipids) able to modulate the activity of the Toll Like Receptor 4 (TLR4) in the perspective to develop new generations of TLR-directed therapeutics. F. Peri did several activities for the technology transfer of the University of Milano-Bicocca, he is administrator of the Foundation U4i (University for Innovation) for the valorization of Research and Technology Transfer of the University of Milano-Bicocca, and he created his spin-off (C2P2 srl).
Link di approfondimento
Didattica
A.A.: 2021/2022
Ricerca
The research activity of F. Peri group (http://theperilaboratory.btbs.unimib.it ) spans the fields of organic chemistry, medicinal chemistry and chemical biology. Development of new drug leads: synthetic molecules and natural compounds.
1. Synthesis and biological characterization of small molecules (mainly cationic and anionic glycolipids) able to modulate the activity of the Toll Like Receptor 4 (TLR4) in the perspective to develop new generations of TLR4-directed therapeutics. Synthesis and biological characterization of new molecules active on TLR4 signaling. New anti-inflammatory compounds targeting TLRs, including compounds targeting IBDs, neuro-inflammations, Amyotrophic Lateral Sclerosis (ALS) and Rheumatoid Arthritis. New vaccine adjuvants based on TLR4 agonists.
Coordination of the H2020-funded MSCA-ETN project TOLLerant (“Toll-Like Receptor 4 activation and function in diseases: an integrated chemical-biology approach”, GA number 642157).
2. Synthesis of new steroid derivatives active against hearth failure. Development of drug leads targeting the protein Serca 2a. This project is based on international patents, in collaboration with the company Windtree (USA).
3. Characterization of anti-inflammatory properties of natural compounds from exctracts (coffee, argan oil, etc…)
Funding and grants
2010-2011: Unit coordinator of PRIN grant from Italian Ministry of University and Research (MIUR), title of the project: New multivalent ligands for human galectins as diagnostic and therapeutic agents (3 years grant, 130.000 E for the research unit)
2009-2014: Unit coordinator in the NIH grant AI 59372 “Regulation of MD-2 function and expression”, in collaboration with J. Weiss and T. Gioannini (University of Iowa) (5 years, 50.000 E/year )
2010-2013: Unit coordinator in NEDD grant, design on novel pharmaceutically active compounds (80.000E, 2 years).
2013-2016: Unit coordinator of PRIN grant from Italian Ministry of University and Research (MIUR), title of the project: “Italian network for the development of multivalent nanosystems (MULTINANOITA)” (3 years grant, 53.000 E for the research unit)
2015-2018: Coordinator of Horizon 2020-funded MSCA-ETN project TOLLerant “Toll like Receptor 4 activation and function in diseases: an integrated chemical biology approach”, Grant Agreement number 642157, consortium of 8 academic and 2 industrial groups, 13 ESR recruited in 2015.
2016-2018: PI in the bilateral project with South Korea (prof. Sung You Hung, Ulsan) founded by Italian Ministry of Foreign Affairs (MAECI)
2019-2023: beneficiary of the MSCA-ETN project BactiVax
Pubblicazioni
- Franco, A., & Peri, F. (2021). Developing New Anti-Tuberculosis Vaccines: Focus on Adjuvants. CELLS, 10(1) [10.3390/cells10010078]. Dettaglio
- Tisi, R., Spinelli, M., Palmioli, A., Airoldi, C., Cazzaniga, P., Besozzi, D., et al. (2021). The Multi-Level Mechanism of Action of a Pan-Ras Inhibitor Explains its Antiproliferative Activity on Cetuximab-Resistant Cancer Cells. FRONTIERS IN MOLECULAR BIOSCIENCES, 8(17 February 2021) [10.3389/fmolb.2021.625979]. Dettaglio
- De Filippis, L., & Peri, F. (2020). The Role of TLR4 in Neural Stem Cells–Mediated Neurogenesis and Neuroinflammation. In The Role of Toll-Like Receptor 4 in Infectious and Non Infectious Inflammation (pp. 129-141). Springer Nature. Dettaglio
- Facchini, F., Di Fusco, D., Barresi, S., Luraghi, A., Minotti, A., Granucci, F., et al. (2020). Effect of chemical modulation of toll-like receptor 4 in an animal model of ulcerative colitis. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 76(3), 409-418 [10.1007/s00228-019-02799-7]. Dettaglio
- Cochet, F., Facchini, F., Zaffaroni, L., Billod, J., Coelho, H., Holgado, A., et al. (2019). Novel carboxylate-based glycolipids: TLR4 antagonism, MD-2 binding and self-assembly properties. SCIENTIFIC REPORTS, 9(1) [10.1038/s41598-018-37421-w]. Dettaglio
